On March 26, 2026, Kodiak Sciences reported positive topline results from GLOW2, its second Phase 3 trial in diabetic retinopathy, where Zenkuda given on a six-month dosing interval showed clear superiority to sham. In the 48-week study, 62.5% of Zenkuda-treated patients achieved at least a two-step improvement in diabetic retinopathy severity versus 3.3% on sham, and the therapy cut the risk of sight-threatening complications by 85% while delivering favorable safety outcomes.
The trial extended the earlier GLOW1 findings to a broader, higher-risk population including proliferative diabetic retinopathy and mild diabetic macular edema, and demonstrated consistent efficacy regardless of patients’ concomitant GLP-1 use. With GLOW2 validating strong efficacy, durability, and safety using its enhanced commercial formulation, Kodiak now views Zenkuda as having a multi-indication, BLA-ready profile and sees supportive read-through for its broader ABC-based pipeline, potentially strengthening its competitive position in retinal therapeutics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.